Long for a Longtime or until they make me an offer I cant' Refuse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I disagree, I think INTL should back up the truck and short the sheet out of AVXL.
Good Luck to him!!!! LOL
Update to Ph2a says it all...
Update on on-going phase 2a trial of new exploratory Alzheimer’s
drug ANAVEX 2-73
We have been told many times 12 week data would be presented..
up·date (up-dat')
tr.v. up·dat·ed, up·dat·ing, up·dates
1. To alter so as to be up to date: update a textbook; update the files.
2. To inform (someone) with the latest information.
n. (up'dat')
1. Information that updates something or someone.
2. The act or an instance of bringing something or someone up to date.
3. An updated version of something.
A Double Whammy! .....lets see how the crooks play this one.
http://www.siumed.edu/cpd/alzheimer/pdf/Program_2016.pdf
Page 23
12:20 – 12:40 Christopher U. Missling (New York, USA)
Update on on-going phase 2a trial of new exploratory Alzheimer’s
drug ANAVEX 2-73
(supported by Anavex Life Sciences Corp.)
http://www.siumed.edu/cpd/alzheimer/pdf/Program_2016.pdf
here is a link... Missling is presenting..
12:20 – 12:40 Christopher U. Missling (New York, USA)
Update on on-going phase 2a trial of new exploratory Alzheimer’s
drug ANAVEX 2-73
(supported by Anavex Life Sciences Corp.)
We have confirmation!
The silence is deafening!
Interesting read:
http://www.telegraph.co.uk/news/health/elder/12174547/Dementia-cure-may-be-just-five-years-away-says-world-expert.html
BTW...Socialism don't and never has worked...
Alzheimer’s Disease
Those considerations will be even more important for another challenging area of drug development -- Alzheimer’s disease. Drugmakers have spent billions of dollars trying and failing to bring to market a treatment that slows the progression of the neurodegenerative disease.
About 5 million Americans have Alzheimer’s, which is the sixth leading cause of death in the U.S., according to the Alzheimer’s Association. For drugs that could treat it, the agency wants to be able to capture signs of benefit, even if they’re tiny. “We don’t want to rule out drugs that only work a little bit,” she said.
Companies like Eli Lilly & Co. are using sensitive tests that measure early signs of cognitive decline, even before traditional symptoms of dementia start to appear.
“We would do an accelerated approval if you could slow decline on these sensitive tests,” Woodcock said.
http://www.bloomberg.com/news/articles/2016-02-26/tragic-patient-stories-don-t-trump-weak-data-fda-official-says
Here is a link for you....ask your buddy AF to explain it to you...
http://smithonstocks.com/illegal-naked-short-selling-appears-to-lie-at-the-heart-of-an-extensive-stock-manipulation-scheme/
Follow the $$$$$$.
You could be right....The Good Doctor would be stealing the thunder from the next session:
Session V. Commercialization Strategies: Developing Science into Products
Chair: Frank Longo, MD, PhD—Stanford University and PharmatrophiX
Several people I respect, including Sheff and AF
What else is there to say!
Let me understand this...are you saying this stock has not been manipulated?
You got it....he never mentioned part 2b in other PR's
My latest guess on 12 week data announcement.. Today the good doctor confirmed it would be at a scientific conference.
http://www.ad-springfield.com/
3/10 10:40 - 11:00 slot
10:40 – 11:00 State of the art lecture
tba (Ness Ziona, Israel)
A unique target for a comprehensive therapy of Alzheimer’s disease: concomitant
activation of SIGMA/M1 muscarinic receptors
Looks like our positive painter is still here!
most likely all or nothing orders...IMO
Question for people that know...Can the trials for Rett and epilepsy be combined and maybe funded by both groups?
Management of the symptoms is done through a multidisciplinary approach utilizing medication for motor difficulties, breathing irregularities, and control of seizures through anticonvulsant drugs
sounds like a cache problem... I hate when that happens...
Papa Troll is at it again....
At this pace, there won’t be a mouse disease $AVXL can’t cure.
— Adam Feuerstein ✡️ (@adamfeuerstein) February 25, 2016
Leader of the Rett syndrome Natural History Study, Alan Percy, MD, stated: “Given the strong clinical safety data profile of ANAVEX 2-73, it would be encouraging to explore the compound in patients with Rett syndrome, which is a very vulnerable patient population that in addition to its neurodevelopmental symptoms also experience a significant number of seizures.”
As the world’s leading private funder of Rett research, they have funded more than $35 million in peer-reviewed research grants and programs to date.
Will funding be announced for this study?
Good Chance...
2:05 – 4:45 Session IX: Clinical Drugs
My bad!
Anavex Life Sciences Corp. director was just granted 54,500 options
http://www.conferencecalltranscripts.org/4/summary2/?id=2456032
I wonder what milestone Dr. Favus achieved..
“The expertise that Dr. Favus brings to Anavex is exceptionally complementary. His significant insights into successful business models and clinical trial and commercialization strategies, developed through in-depth analysis of healthcare companies, are expected to be extremely beneficial. On behalf of Anavex and the Board of Directors, I welcome both Dr. Favus and Dr. Metzner and look forward to drawing upon their strategic, operational and clinical judgment.”
We should get a PR about the 2016 Epilepsy conference...and hopefully some other goodies...
Epilepsy trials should be simpler...It either works or not....
Like the good doctor said quick to market...
After the 29th....We don't want a good PR getting lost in a sea of Classless Action noise.
More positive anavex info...last two paragraphs... http://www.nrronline.org/article.asp?issn=1673-5374%3Byear%3D2016%3Bvolume%3D11%3Bissue%3D1%3Bspage%3D79%3Bepage%3D80%3Baulast%3DKoshibu
The bottom line for any stock is supply and demand...with a good PR the PPS will rise quickly... I like the fact that our float is very low... FRROL continues to beat a dead horse IMO.
No $4 options
Keep in mind they can sell naked calls to hedge their shorts.
Look at open interest on the Feb $5 calls... I have seen this many times over the years. The crooks will ping the $5 calls and let them expire worthless. The only winners are the folks that sold those calls.
They will ping the $5 options today... IMO
MS AD Parkinson's Epilepsy and likely many more.
How much is this platform drug worth.
The 12 week (30) and 26 week (14 or more) data will be "HUGE".
Good Luck to all longs.
Patience is a virtue and in the case of Anavex it is a necessity...It will be very good or not... I am patient..
A ray of sunshine on a gloomy day... Thanks Tom ;)